Weaver C. Barksdale & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-12,617	Closed	-$712K	–	547
2015 Q3	$712K	Hold	12,617	–	–	0.57%	67
2015 Q2	$746K	Hold	12,617	–	–	0.55%	72
2015 Q1	$786K	Hold	12,617	–	–	0.59%	60
2014 Q4	$726K	Sell	12,617 -58	-0.5%	-$3.23K	0.58%	73
2014 Q3	$681K	Sell	12,675 -2,578	-17%	-$137K	0.56%	73
2014 Q2	$800K	Hold	15,253	–	–	0.64%	49
2014 Q1	$806K	Buy	15,253 +1,935	+15%	+$89.4K	0.67%	40
2013 Q4	$534K	Buy	13,318 +5,828	+78%	+$229K	0.45%	75
2013 Q3	$283K	Buy	+7,490	New	+$292K	0.26%	96

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Weaver C. Barksdale & Associates's TEVA Position: Q4 2015 in Review

Weaver C. Barksdale & Associates sold out of Teva Pharmaceuticals (TEVA) in Q4 2015, closing a stake of 12,617 shares — an estimated $712K sold.

Weaver C. Barksdale & Associates first reported a position in TEVA in Q3 2013 and held it in 9 quarters. The position peaked at $806K in Q1 2014. 876 funds tracked by Wall St. Rank hold TEVA as of Q4 2015.

Weaver C. Barksdale & Associates reported no remaining Teva Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Weaver C. Barksdale & Associates sold 12,617 Teva Pharmaceuticals shares in Q4 2015, an estimated $712K.
Weaver C. Barksdale & Associates first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 9 quarters.
Weaver C. Barksdale & Associates's Teva Pharmaceuticals position peaked at $806K in Q1 2014.
876 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2015.

Based on Weaver C. Barksdale & Associates's 13F filing for Q4 2015, filed 25 Jan 2016.